O	0	1	2	2	CD	B-NP
O	1	2	.	.	.	I-NP
O	2	3	2	2	CD	I-NP
O	3	4	.	.	.	O

B-Multi-tissue_structure	5	9	Iris	Iris	NNP	B-NP
O	10	13	and	and	CC	I-NP
B-Multi-tissue_structure	14	21	Ciliary	Ciliary	NNP	I-NP
I-Multi-tissue_structure	22	26	Body	Body	NNP	I-NP

O	27	36	Serotonin	Serotonin	NN	B-NP
O	37	39	is	be	VBZ	B-VP
O	40	47	present	present	JJ	B-ADJP
O	48	50	in	in	IN	B-PP
O	51	60	mammalian	mammalian	JJ	B-ADJP
B-Multi-tissue_structure	61	65	iris	iris	AFX	O
I-Multi-tissue_structure	65	66	-	-	HYPH	B-NP
I-Multi-tissue_structure	66	73	ciliary	ciliary	JJ	I-NP
I-Multi-tissue_structure	74	78	body	body	NN	I-NP
I-Multi-tissue_structure	79	86	complex	complex	NN	I-NP
O	87	88	(	(	(	O
B-Multi-tissue_structure	88	91	ICB	ICB	NN	B-NP
O	91	92	)	)	)	O
O	93	95	at	at	IN	B-PP
O	96	102	higher	high	JJR	B-NP
O	103	116	concentration	concentration	NN	I-NP
O	117	121	that	that	IN	B-SBAR
O	122	124	in	in	IN	B-PP
O	125	128	non	non	AFX	B-NP
O	128	129	-	-	HYPH	I-NP
O	129	138	mammalian	mammalian	JJ	I-NP
O	139	146	species	specie	NNS	I-NP
O	147	148	[	[	(	O
O	148	149	5	5	CD	B-NP
O	149	150	,	,	,	I-NP
O	151	153	45	45	CD	I-NP
O	153	154	,	,	,	I-NP
O	155	157	73	73	CD	I-NP
O	157	158	,	,	,	I-NP
O	159	162	129	129	CD	I-NP
O	162	163	,	,	,	I-NP
O	164	167	137	137	CD	I-NP
O	167	168	]	]	)	O
O	168	169	.	.	.	O

O	170	178	Moreover	Moreover	RB	B-ADVP
O	178	179	,	,	,	O
O	180	183	the	the	DT	B-NP
O	184	192	presence	presence	NN	I-NP
O	193	195	of	of	IN	B-PP
O	196	208	serotonergic	serotonergic	JJ	B-NP
B-Multi-tissue_structure	209	215	nerves	nerve	NNS	I-NP
O	216	219	has	have	VBZ	B-VP
O	220	224	been	be	VBN	I-VP
O	225	237	demonstrated	demonstrate	VBN	I-VP
O	238	240	in	in	IN	B-PP
O	241	248	studies	study	NNS	B-NP
O	249	258	conducted	conduct	VBN	B-VP
O	259	261	on	on	IN	B-PP
O	262	265	the	the	DT	B-NP
B-Multi-tissue_structure	266	269	ICB	ICB	NN	I-NP
O	270	272	of	of	IN	B-PP
O	273	280	various	various	JJ	B-NP
O	281	288	species	specie	NNS	I-NP
O	289	290	[	[	(	O
O	290	293	102	102	CD	B-NP
O	293	294	,	,	,	I-NP
O	295	298	137	137	CD	I-NP
O	298	299	,	,	,	I-NP
O	300	303	138	138	CD	I-NP
O	303	304	]	]	)	O
O	304	305	.	.	.	O

O	306	318	Experimental	Experimental	JJ	B-NP
O	319	327	evidence	evidence	NN	I-NP
O	328	331	and	and	CC	I-NP
O	332	343	radioligand	radioligand	NN	I-NP
O	344	352	analyses	analysis	NNS	I-NP
O	353	357	have	have	VBP	B-VP
O	358	365	defined	define	VBN	I-VP
O	366	369	the	the	DT	B-NP
O	370	378	presence	presence	NN	I-NP
O	379	381	at	at	IN	B-PP
O	382	386	this	this	DT	B-NP
O	387	392	level	level	NN	I-NP
O	393	395	of	of	IN	B-PP
O	396	401	three	three	CD	B-NP
O	402	411	different	different	JJ	I-NP
O	412	417	types	type	NNS	I-NP
O	418	420	of	of	IN	B-PP
O	421	430	serotonin	serotonin	NN	B-NP
O	431	440	receptors	receptor	NNS	I-NP
O	441	442	[	[	(	O
O	442	444	10	10	CD	B-NP
O	444	445	,	,	,	I-NP
O	446	448	28	28	CD	I-NP
O	448	449	,	,	,	I-NP
O	450	452	85	85	CD	I-NP
O	452	453	,	,	,	I-NP
O	454	457	136	136	CD	I-NP
O	457	458	,	,	,	I-NP
O	459	462	137	137	CD	I-NP
O	462	463	]	]	)	O
O	463	464	,	,	,	O
O	465	466	i	i	NN	B-NP
O	466	467	.	.	.	O
O	467	468	e	e	NN	B-NP
O	468	469	.	.	.	O
O	470	471	5	5	CD	B-NP
O	471	472	-	-	HYPH	I-NP
O	472	476	HT1A	HT1A	NN	I-NP
O	476	477	,	,	,	O
O	478	479	5	5	CD	B-NP
O	479	480	-	-	HYPH	I-NP
O	480	484	HT2A	HT2A	NN	I-NP
O	484	485	/	/	SYM	B-NP
O	485	487	2C	2C	NN	I-NP
O	488	491	and	and	CC	O
O	492	493	5	5	CD	B-NP
O	493	494	-	-	HYPH	I-NP
O	494	497	HT7	HT7	NN	I-NP
O	498	499	[	[	(	O
O	499	501	98	98	CD	B-NP
O	501	502	]	]	)	O
O	502	503	,	,	,	O
O	504	507	one	one	CD	B-NP
O	508	514	linked	link	VBD	B-VP
O	515	517	to	to	TO	B-PP
O	518	519	a	a	DT	B-NP
O	520	531	stimulation	stimulation	NN	I-NP
O	532	534	of	of	IN	B-PP
O	535	543	inositol	inositol	NN	B-NP
O	544	554	phosphates	phosphate	NNS	I-NP
O	555	556	(	(	(	O
O	556	557	5	5	CD	B-NP
O	557	558	-	-	HYPH	I-NP
O	558	561	HT2	HT2	NN	I-NP
O	562	569	subtype	subtype	NN	I-NP
O	569	570	)	)	)	O
O	570	571	,	,	,	O
O	572	577	while	while	IN	B-SBAR
O	578	581	the	the	DT	B-NP
O	582	588	others	other	NNS	I-NP
O	589	592	two	two	CD	B-NP
O	593	596	are	be	VBP	B-VP
O	597	603	linked	link	VBN	I-VP
O	604	606	to	to	TO	B-PP
O	607	611	cAMP	cAMP	NN	B-NP
O	612	620	activity	activity	NN	I-NP
O	620	621	.	.	.	O

O	622	625	The	The	DT	B-NP
O	626	638	plausibility	plausibility	NN	I-NP
O	639	641	of	of	IN	B-PP
O	642	645	the	the	DT	B-NP
O	646	655	existence	existence	NN	I-NP
O	656	658	of	of	IN	B-PP
O	659	663	more	more	JJR	B-NP
O	664	668	than	than	IN	I-NP
O	669	672	one	one	CD	I-NP
O	673	674	5	5	CD	I-NP
O	674	675	-	-	HYPH	I-NP
O	675	677	HT	HT	NN	I-NP
O	678	686	receptor	receptor	NN	I-NP
O	687	691	type	type	NN	I-NP
O	692	694	in	in	IN	B-PP
O	695	698	the	the	DT	B-NP
B-Multi-tissue_structure	699	706	ciliary	ciliary	JJ	I-NP
I-Multi-tissue_structure	707	711	body	body	NN	I-NP
O	712	714	is	be	VBZ	B-VP
O	715	724	confirmed	confirm	VBN	I-VP
O	725	727	by	by	IN	B-PP
B-Immaterial_anatomical_entity	728	739	intraocular	intraocular	JJ	B-NP
O	740	748	pressure	pressure	NN	I-NP
O	749	750	(	(	(	O
O	750	753	IOP	IOP	NN	B-NP
O	753	754	)	)	)	O
O	755	766	experiments	experiment	NNS	B-NP
O	766	767	.	.	.	O

O	768	775	Topical	Topical	JJ	B-NP
O	776	787	application	application	NN	I-NP
O	788	790	of	of	IN	B-PP
O	791	800	serotonin	serotonin	NN	B-NP
O	801	804	has	have	VBZ	B-VP
O	805	809	been	be	VBN	I-VP
O	810	818	reported	report	VBN	I-VP
O	819	821	to	to	TO	B-VP
O	822	826	both	both	CC	I-VP
O	827	834	elevate	elevate	VB	I-VP
O	835	836	[	[	(	O
O	836	838	84	84	CD	B-NP
O	838	839	]	]	)	O
O	840	843	and	and	CC	O
O	844	849	lower	low	JJR	B-ADJP
O	850	851	[	[	(	O
O	851	853	88	88	CD	O
O	853	854	]	]	)	O
O	855	858	IOP	IOP	NN	B-NP
O	859	861	in	in	IN	B-PP
O	862	868	rabbit	rabbit	NN	B-NP
O	868	869	.	.	.	O

O	870	871	A	A	DT	B-NP
O	872	877	large	large	JJ	I-NP
O	878	884	number	number	NN	I-NP
O	885	887	of	of	IN	B-PP
O	888	895	reports	report	NNS	B-NP
O	896	900	have	have	VBP	B-VP
O	901	906	shown	show	VBN	I-VP
O	907	911	that	that	IN	B-SBAR
O	912	921	serotonin	serotonin	NN	B-NP
O	922	930	agonists	agonist	NNS	I-NP
O	931	934	and	and	CC	I-NP
O	935	946	antagonists	antagonist	NNS	I-NP
O	947	950	can	can	MD	B-VP
O	951	958	produce	produce	VB	I-VP
O	959	968	increases	increase	NNS	B-NP
O	969	972	and	and	CC	O
O	973	982	decreases	decrease	VBZ	B-VP
O	983	985	in	in	IN	B-PP
O	986	989	IOP	IOP	NN	B-NP
O	990	994	when	when	WRB	B-ADVP
O	995	1000	given	give	VBN	B-VP
B-Organism_subdivision	1001	1007	orally	orally	RB	B-ADVP
O	1007	1008	,	,	,	O
O	1009	1018	topically	topically	RB	B-ADVP
O	1019	1021	to	to	TO	B-PP
O	1022	1025	the	the	DT	B-NP
B-Organ	1026	1029	eye	eye	NN	I-NP
O	1030	1032	or	or	CC	O
O	1033	1037	when	when	WRB	B-ADVP
O	1038	1042	they	they	PRP	B-NP
O	1043	1046	are	be	VBP	B-VP
O	1047	1055	directly	directly	RB	I-VP
O	1056	1064	injected	inject	VBN	I-VP
O	1065	1067	in	in	IN	B-PP
O	1068	1071	the	the	DT	B-NP
B-Multi-tissue_structure	1072	1080	anterior	anterior	JJ	I-NP
I-Multi-tissue_structure	1081	1088	chamber	chamber	NN	I-NP
O	1089	1090	[	[	(	I-NP
O	1090	1092	10	10	CD	I-NP
O	1092	1093	,	,	,	I-NP
O	1094	1096	26	26	CD	I-NP
O	1096	1097	,	,	,	I-NP
O	1098	1100	34	34	CD	I-NP
O	1100	1101	,	,	,	I-NP
O	1102	1104	35	35	CD	I-NP
O	1104	1105	,	,	,	I-NP
O	1106	1108	64	64	CD	I-NP
O	1108	1109	,	,	,	I-NP
O	1110	1112	75	75	CD	I-NP
O	1112	1113	,	,	,	I-NP
O	1114	1116	84	84	CD	I-NP
O	1116	1117	,	,	,	I-NP
O	1118	1120	87	87	CD	I-NP
O	1120	1121	,	,	,	I-NP
O	1122	1124	88	88	CD	I-NP
O	1124	1125	,	,	,	I-NP
O	1126	1129	112	112	CD	I-NP
O	1129	1130	,	,	,	I-NP
O	1131	1134	113	113	CD	I-NP
O	1134	1135	,	,	,	I-NP
O	1136	1139	126	126	CD	I-NP
O	1139	1140	,	,	,	I-NP
O	1141	1144	136	136	CD	I-NP
O	1144	1145	,	,	,	I-NP
O	1146	1149	137	137	CD	I-NP
O	1149	1150	]	]	)	O
O	1150	1151	.	.	.	O

O	1152	1153	A	A	DT	B-NP
O	1154	1163	rationale	rationale	NN	I-NP
O	1164	1167	for	for	IN	B-PP
O	1168	1172	such	such	JJ	B-NP
O	1173	1183	apparently	apparently	RB	I-NP
O	1184	1197	contradictory	contradictory	JJ	I-NP
O	1198	1205	results	result	NNS	I-NP
O	1206	1209	may	may	MD	B-VP
O	1210	1212	be	be	VB	I-VP
O	1213	1216	due	due	JJ	B-ADVP
O	1217	1219	to	to	TO	B-PP
O	1220	1223	the	the	DT	B-NP
O	1224	1233	different	different	JJ	I-NP
O	1234	1239	sites	site	NNS	I-NP
O	1240	1242	of	of	IN	B-PP
O	1243	1249	action	action	NN	B-NP
O	1249	1250	,	,	,	O
O	1251	1252	i	i	NN	B-NP
O	1252	1253	.	.	.	I-NP
O	1253	1254	e	e	NN	I-NP
O	1254	1255	.	.	.	O
O	1256	1261	which	which	WDT	B-NP
O	1262	1267	class	class	NN	I-NP
O	1268	1270	of	of	IN	B-PP
O	1271	1280	serotonin	serotonin	NN	B-NP
O	1281	1289	receptor	receptor	NN	I-NP
O	1290	1292	is	be	VBZ	B-VP
O	1293	1302	activated	activate	VBN	I-VP
O	1302	1303	.	.	.	O

O	1304	1306	In	In	IN	B-PP
O	1307	1311	fact	fact	NN	B-NP
O	1311	1312	,	,	,	O
O	1313	1315	in	in	IN	B-PP
O	1316	1322	rabbit	rabbit	NN	B-NP
O	1323	1326	the	the	DT	B-NP
O	1327	1341	administration	administration	NN	I-NP
O	1342	1344	of	of	IN	B-PP
O	1345	1346	5	5	CD	B-NP
O	1346	1347	-	-	HYPH	I-NP
O	1347	1353	methyl	methyl	NN	I-NP
O	1353	1354	-	-	HYPH	B-NP
O	1354	1362	urapidil	urapidil	NN	I-NP
O	1363	1364	(	(	(	O
O	1364	1365	a	a	DT	B-NP
O	1366	1374	combined	combine	VBN	I-NP
O	1375	1376	5	5	CD	I-NP
O	1376	1377	-	-	HYPH	I-NP
O	1377	1381	HT1A	HT1A	NN	I-NP
O	1382	1389	agonist	agonist	NN	I-NP
O	1389	1390	/	/	SYM	B-NP
O	1390	1396	alpha1	alpha1	NN	I-NP
O	1397	1411	adrenoreceptor	adrenoreceptor	NN	I-NP
O	1412	1422	antagonist	antagonist	NN	I-NP
O	1422	1423	)	)	)	O
O	1424	1427	and	and	CC	O
O	1428	1429	8	8	CD	B-NP
O	1429	1430	-	-	HYPH	I-NP
O	1430	1432	OH	OH	NN	I-NP
O	1432	1433	-	-	HYPH	O
O	1433	1437	DPAT	DPAT	NN	B-NP
O	1438	1439	(	(	(	O
O	1439	1440	8	8	CD	B-NP
O	1440	1441	-	-	HYPH	I-NP
O	1441	1469	hydroxydypropylaminotetralin	hydroxydypropylaminotetralin	NN	I-NP
O	1469	1470	,	,	,	O
O	1471	1472	a	a	DT	B-NP
O	1473	1478	5HT1A	5HT1A	NN	I-NP
O	1479	1486	agonist	agonist	NN	I-NP
O	1486	1487	)	)	)	O
O	1488	1495	reduces	reduce	VBZ	B-VP
O	1496	1499	IOP	IOP	NN	B-NP
O	1499	1500	,	,	,	O
O	1501	1506	while	while	IN	B-SBAR
O	1507	1510	the	the	DT	B-NP
O	1511	1525	administration	administration	NN	I-NP
O	1526	1528	of	of	IN	B-PP
O	1529	1530	5	5	CD	B-NP
O	1530	1531	-	-	HYPH	I-NP
O	1531	1533	CT	CT	NN	I-NP
O	1534	1535	(	(	(	O
O	1535	1536	5	5	CD	B-NP
O	1536	1537	-	-	HYPH	I-NP
O	1537	1558	carboxamidotryptamine	carboxamidotryptamine	NN	I-NP
O	1558	1559	,	,	,	O
O	1560	1561	a	a	DT	B-NP
O	1562	1563	5	5	CD	I-NP
O	1563	1564	-	-	HYPH	I-NP
O	1564	1568	HT1A	HT1A	NN	I-NP
O	1569	1572	and	and	CC	I-NP
O	1573	1574	5	5	CD	I-NP
O	1574	1575	-	-	HYPH	I-NP
O	1575	1578	HT7	HT7	NN	I-NP
O	1579	1586	agonist	agonist	NN	I-NP
O	1586	1587	)	)	)	O
O	1588	1597	increases	increase	VBZ	B-VP
O	1598	1601	IOP	IOP	NN	B-NP
O	1602	1603	[	[	(	O
O	1603	1605	36	36	CD	B-NP
O	1605	1606	,	,	,	I-NP
O	1607	1609	84	84	CD	I-NP
O	1609	1610	,	,	,	I-NP
O	1611	1613	99	99	CD	I-NP
O	1613	1614	]	]	)	O
O	1614	1615	.	.	.	O

O	1616	1623	Chidlow	Chidlow	NNP	B-NP
O	1623	1624	,	,	,	O
O	1625	1627	Le	Le	NNP	B-NP
O	1628	1633	Corre	Corre	NNP	I-NP
O	1634	1637	and	and	CC	I-NP
O	1638	1645	Osborne	Osborne	NNP	I-NP
O	1646	1647	[	[	(	O
O	1647	1649	28	28	CD	B-NP
O	1649	1650	]	]	)	O
O	1651	1655	have	have	VBP	B-VP
O	1656	1664	recently	recently	RB	I-VP
O	1665	1677	demonstrated	demonstrate	VBN	I-VP
O	1678	1682	that	that	IN	B-SBAR
O	1682	1683	,	,	,	O
O	1684	1686	in	in	IN	B-PP
B-Multi-tissue_structure	1687	1694	section	section	NN	B-NP
O	1695	1700	taken	take	VBN	B-VP
O	1701	1708	through	through	IN	B-PP
O	1709	1712	the	the	DT	B-NP
O	1713	1718	whole	whole	JJ	I-NP
B-Organ	1719	1722	eye	eye	NN	I-NP
O	1723	1726	and	and	CC	O
B-Multi-tissue_structure	1727	1734	ciliary	ciliary	JJ	B-NP
I-Multi-tissue_structure	1735	1739	body	body	NN	I-NP
O	1739	1740	,	,	,	O
O	1741	1750	prominent	prominent	JJ	B-NP
O	1751	1752	5	5	CD	I-NP
O	1752	1753	-	-	HYPH	I-NP
O	1753	1757	HT1A	HT1A	NN	I-NP
O	1758	1761	and	and	CC	I-NP
O	1762	1763	5	5	CD	I-NP
O	1763	1764	-	-	HYPH	I-NP
O	1764	1767	HT7	HT7	NN	I-NP
O	1768	1776	receptor	receptor	NN	I-NP
O	1777	1786	messenger	messenger	NN	I-NP
O	1787	1798	ribonucleic	ribonucleic	JJ	I-NP
O	1799	1803	acid	acid	NN	I-NP
O	1804	1811	signals	signal	NNS	I-NP
O	1812	1816	were	be	VBD	B-VP
O	1817	1825	obtained	obtain	VBN	I-VP
O	1825	1826	.	.	.	O

O	1827	1832	These	These	DT	B-NP
O	1833	1840	signals	signal	NNS	I-NP
O	1841	1845	were	be	VBD	B-VP
O	1846	1853	evident	evident	JJ	B-ADJP
O	1854	1856	in	in	IN	B-PP
O	1857	1861	both	both	CC	B-NP
O	1862	1865	the	the	DT	I-NP
O	1866	1875	pigmented	pigmented	JJ	I-NP
O	1876	1879	and	and	CC	I-NP
O	1880	1883	non	non	AFX	I-NP
O	1883	1884	-	-	HYPH	I-NP
O	1884	1893	pigmented	pigment	VBN	B-VP
B-Cell	1894	1904	epithelial	epithelial	JJ	B-NP
I-Cell	1905	1909	cell	cell	NN	I-NP
O	1910	1916	layers	layer	NNS	I-NP
O	1917	1919	of	of	IN	B-PP
O	1920	1923	the	the	DT	B-NP
B-Multi-tissue_structure	1924	1928	pars	par	NNS	I-NP
I-Multi-tissue_structure	1929	1936	plicata	plicata	NN	I-NP
O	1937	1943	region	region	NN	I-NP
O	1944	1946	of	of	IN	B-PP
O	1947	1950	the	the	DT	B-NP
B-Multi-tissue_structure	1951	1958	ciliary	ciliary	JJ	I-NP
O	1959	1968	processes	process	NNS	I-NP
O	1968	1969	,	,	,	B-PP
O	1970	1973	but	but	CC	I-PP
O	1974	1977	not	not	RB	B-PP
O	1978	1980	in	in	IN	I-PP
O	1981	1984	the	the	DT	B-NP
B-Multi-tissue_structure	1985	1989	pars	par	NNS	I-NP
I-Multi-tissue_structure	1990	1995	plana	plana	NN	I-NP
O	1996	1998	or	or	CC	B-PP
O	1999	2001	in	in	IN	B-PP
O	2002	2005	the	the	DT	B-NP
B-Multi-tissue_structure	2006	2013	ciliary	ciliary	JJ	I-NP
I-Multi-tissue_structure	2014	2025	musculature	musculature	NN	I-NP
O	2025	2026	.	.	.	O

O	2027	2028	5	5	CD	B-NP
O	2028	2029	-	-	HYPH	I-NP
O	2029	2033	HT1A	HT1A	NN	I-NP
O	2034	2037	and	and	CC	I-NP
O	2038	2039	5	5	CD	I-NP
O	2039	2040	-	-	HYPH	I-NP
O	2040	2043	HT7	HT7	NN	I-NP
O	2044	2051	signals	signal	NNS	I-NP
O	2052	2056	were	be	VBD	B-VP
O	2057	2065	apparent	apparent	JJ	B-ADJP
O	2066	2068	in	in	IN	B-PP
O	2069	2072	the	the	DT	B-NP
O	2073	2082	posterior	posterior	JJ	I-NP
O	2083	2092	processes	process	NNS	I-NP
O	2093	2096	but	but	CC	B-PP
O	2097	2100	not	not	RB	B-PP
O	2101	2103	in	in	IN	I-PP
O	2104	2107	the	the	DT	B-NP
B-Multi-tissue_structure	2108	2112	iris	iris	NN	I-NP
O	2113	2122	processes	process	NNS	I-NP
O	2122	2123	.	.	.	O

O	2124	2127	The	The	DT	B-NP
O	2128	2136	presence	presence	NN	I-NP
O	2137	2139	of	of	IN	B-PP
O	2140	2144	both	both	DT	B-NP
O	2145	2154	receptors	receptor	NNS	I-NP
O	2155	2157	in	in	IN	B-PP
O	2158	2161	the	the	DT	B-NP
B-Multi-tissue_structure	2162	2169	ciliary	ciliary	JJ	I-NP
I-Multi-tissue_structure	2170	2174	body	body	NN	I-NP
O	2175	2180	would	would	MD	B-VP
O	2181	2190	certainly	certainly	RB	I-VP
O	2191	2198	provide	provide	VB	I-VP
O	2199	2201	an	an	DT	B-NP
O	2202	2213	explanation	explanation	NN	I-NP
O	2214	2217	for	for	IN	B-PP
O	2218	2221	the	the	DT	B-NP
O	2222	2229	shallow	shallow	JJ	I-NP
O	2230	2242	displacement	displacement	NN	I-NP
O	2243	2249	curves	curve	NNS	I-NP
O	2250	2258	observed	observe	VBN	B-VP
O	2259	2261	in	in	IN	B-PP
O	2262	2263	[	[	(	O
O	2263	2265	3H	3H	NN	B-NP
O	2265	2266	]	]	)	O
O	2266	2267	5	5	CD	B-NP
O	2267	2268	-	-	HYPH	I-NP
O	2268	2270	HT	HT	NN	I-NP
O	2271	2278	binding	binding	NN	I-NP
O	2279	2286	studies	study	NNS	I-NP
O	2287	2291	with	with	IN	B-PP
O	2292	2295	the	the	DT	B-NP
B-Tissue	2296	2302	tissue	tissue	NN	I-NP
O	2303	2304	[	[	(	O
O	2304	2307	110	110	CD	B-NP
O	2307	2308	]	]	)	O
O	2308	2309	,	,	,	O
O	2310	2315	since	since	IN	B-SBAR
O	2316	2320	this	this	DT	B-NP
O	2321	2327	ligand	ligand	NN	I-NP
O	2328	2331	can	can	MD	B-VP
O	2332	2334	be	be	VB	I-VP
O	2335	2339	used	use	VBN	I-VP
O	2340	2342	to	to	TO	B-VP
O	2343	2348	label	label	VB	I-VP
O	2349	2353	both	both	DT	B-NP
O	2354	2363	receptors	receptor	NNS	I-NP
O	2363	2364	.	.	.	O

O	2365	2372	Because	Because	IN	B-SBAR
O	2373	2376	the	the	DT	B-NP
B-Tissue	2377	2384	ciliary	ciliary	JJ	I-NP
I-Tissue	2385	2395	epithelium	epithelium	NN	I-NP
O	2396	2398	of	of	IN	B-PP
O	2399	2402	the	the	DT	B-NP
B-Multi-tissue_structure	2403	2407	pars	par	NNS	I-NP
I-Multi-tissue_structure	2408	2415	plicata	plicata	NN	I-NP
O	2416	2418	is	be	VBZ	B-VP
O	2419	2430	responsible	responsible	JJ	B-ADJP
O	2431	2434	for	for	IN	B-PP
O	2435	2438	the	the	DT	B-NP
O	2439	2448	secretion	secretion	NN	I-NP
O	2449	2451	of	of	IN	B-PP
B-Organism_substance	2452	2459	aqueous	aqueous	JJ	B-NP
I-Organism_substance	2460	2465	humor	humor	NN	I-NP
O	2465	2466	,	,	,	O
O	2467	2469	an	an	DT	B-NP
O	2470	2477	obvious	obvious	JJ	I-NP
O	2478	2486	function	function	NN	I-NP
O	2487	2490	for	for	IN	B-PP
O	2491	2496	these	these	DT	B-NP
O	2497	2500	two	two	CD	I-NP
O	2501	2510	receptors	receptor	NNS	I-NP
O	2511	2516	would	would	MD	B-VP
O	2517	2519	be	be	VB	I-VP
O	2520	2522	an	an	DT	B-NP
O	2523	2534	involvement	involvement	NN	I-NP
O	2535	2537	in	in	IN	B-PP
O	2538	2541	the	the	DT	B-NP
O	2542	2549	control	control	NN	I-NP
O	2550	2552	of	of	IN	B-PP
O	2553	2560	aqueous	aqueous	JJ	B-NP
O	2561	2571	production	production	NN	I-NP
O	2572	2575	and	and	CC	O
O	2575	2576	,	,	,	O
O	2577	2589	consequently	consequently	RB	B-ADVP
O	2589	2590	,	,	,	O
O	2591	2593	of	of	IN	B-PP
O	2594	2597	the	the	DT	B-NP
O	2598	2601	IOP	IOP	NN	I-NP
O	2602	2607	level	level	NN	I-NP
O	2607	2608	.	.	.	O

O	2609	2616	Further	Further	RB	B-ADVP
O	2616	2617	,	,	,	O
O	2618	2621	the	the	DT	B-NP
O	2622	2628	almost	almost	RB	I-NP
O	2629	2638	identical	identical	JJ	I-NP
O	2639	2651	distribution	distribution	NN	I-NP
O	2652	2654	of	of	IN	B-PP
O	2655	2658	the	the	DT	B-NP
O	2659	2660	5	5	CD	I-NP
O	2660	2661	-	-	HYPH	I-NP
O	2661	2665	HT1A	HT1A	NN	I-NP
O	2666	2669	and	and	CC	I-NP
O	2670	2671	5	5	CD	I-NP
O	2671	2672	-	-	HYPH	I-NP
O	2672	2675	HT7	HT7	NN	I-NP
O	2676	2686	messengers	messenger	NNS	I-NP
O	2687	2698	ribonucleic	ribonucleic	JJ	B-NP
O	2699	2703	acid	acid	NN	I-NP
O	2704	2712	indicate	indicate	VBP	B-VP
O	2713	2717	that	that	IN	B-SBAR
O	2718	2721	the	the	DT	B-NP
O	2722	2731	receptors	receptor	NNS	I-NP
O	2732	2735	may	may	MD	B-VP
O	2736	2738	be	be	VB	I-VP
O	2739	2741	co	co	AFX	B-ADJP
O	2741	2742	-	-	HYPH	I-ADJP
O	2742	2751	localized	localized	JJ	I-ADJP
O	2752	2754	in	in	IN	B-PP
B-Cell	2755	2765	epithelial	epithelial	JJ	B-NP
I-Cell	2766	2771	cells	cell	NNS	I-NP
O	2771	2772	.	.	.	O

O	2773	2776	The	The	DT	B-NP
O	2777	2785	presence	presence	NN	I-NP
O	2786	2788	of	of	IN	B-PP
O	2789	2792	two	two	CD	B-NP
O	2793	2802	serotonin	serotonin	NN	I-NP
O	2803	2812	receptors	receptor	NNS	I-NP
O	2813	2817	with	with	IN	B-PP
O	2818	2826	opposing	opposing	JJ	B-NP
O	2827	2834	effects	effect	NNS	I-NP
O	2835	2837	on	on	IN	B-PP
O	2838	2842	cAMP	cAMP	NN	B-NP
O	2843	2845	in	in	IN	B-PP
O	2846	2849	the	the	DT	B-NP
O	2850	2854	same	same	JJ	I-NP
B-Cell	2855	2859	cell	cell	NN	I-NP
O	2860	2865	layer	layer	NN	I-NP
O	2866	2873	prompts	prompt	VBZ	B-VP
O	2874	2877	the	the	DT	B-NP
O	2878	2888	suggestion	suggestion	NN	I-NP
O	2889	2893	that	that	IN	B-SBAR
O	2894	2898	they	they	PRP	B-NP
O	2899	2904	could	could	MD	B-VP
O	2905	2908	act	act	VB	I-VP
O	2909	2925	antagonistically	antagonistically	RB	B-ADVP
O	2925	2926	.	.	.	O

O	2927	2930	The	The	DT	B-NP
O	2931	2938	agonism	agonism	NN	I-NP
O	2939	2941	of	of	IN	B-PP
O	2942	2943	5	5	CD	B-NP
O	2943	2944	-	-	HYPH	I-NP
O	2944	2948	HT1A	HT1A	NN	I-NP
O	2949	2958	receptors	receptor	NNS	I-NP
O	2958	2959	,	,	,	O
O	2960	2970	negatively	negatively	RB	B-VP
O	2971	2978	coupled	couple	VBN	I-VP
O	2979	2981	to	to	TO	B-PP
O	2982	2986	cAMP	cAMP	NN	B-NP
O	2986	2987	,	,	,	O
O	2988	2995	reduces	reduce	VBZ	B-VP
O	2996	2999	IOP	IOP	NN	B-NP
O	3000	3002	by	by	IN	B-PP
O	3003	3013	decreasing	decrease	VBG	B-VP
O	3014	3017	the	the	DT	B-NP
O	3018	3028	production	production	NN	I-NP
O	3029	3031	of	of	IN	B-PP
B-Organism_substance	3032	3039	aqueous	aqueous	JJ	B-NP
I-Organism_substance	3040	3045	humor	humor	NN	I-NP
O	3045	3046	,	,	,	O
O	3047	3051	like	like	IN	B-PP
O	3052	3056	beta	beta	SYM	B-NP
O	3056	3057	-	-	HYPH	B-NP
O	3057	3065	receptor	receptor	NN	I-NP
O	3066	3077	antagonists	antagonist	NNS	I-NP
O	3078	3083	which	which	WDT	B-NP
O	3083	3084	,	,	,	O
O	3085	3096	diminishing	diminish	VBG	B-VP
O	3097	3100	the	the	DT	B-NP
O	3101	3108	content	content	NN	I-NP
O	3109	3111	of	of	IN	B-PP
O	3112	3116	cAMP	cAMP	NN	B-NP
O	3117	3119	at	at	IN	B-PP
O	3120	3123	the	the	DT	B-NP
O	3124	3138	postjunctional	postjunctional	JJ	I-NP
O	3139	3143	site	site	NN	I-NP
O	3143	3144	,	,	,	O
O	3145	3151	lowers	lower	VBZ	B-VP
O	3152	3155	the	the	DT	B-NP
B-Organism_substance	3156	3163	aqueous	aqueous	JJ	I-NP
I-Organism_substance	3164	3169	humor	humor	NN	I-NP
O	3170	3179	secretion	secretion	NN	I-NP
O	3180	3184	with	with	IN	B-PP
O	3185	3186	a	a	DT	B-NP
O	3187	3197	consequent	consequent	JJ	I-NP
O	3198	3206	decrease	decrease	NN	I-NP
O	3207	3209	in	in	IN	B-PP
O	3210	3213	IOP	IOP	NN	B-NP
O	3214	3215	[	[	(	O
O	3215	3217	98	98	CD	B-NP
O	3217	3218	]	]	)	O
O	3218	3219	.	.	.	O

O	3220	3222	On	On	IN	B-PP
O	3223	3226	the	the	DT	B-NP
O	3227	3235	contrary	contrary	NN	I-NP
O	3235	3236	,	,	,	O
O	3237	3240	the	the	DT	B-NP
O	3241	3255	administration	administration	NN	I-NP
O	3256	3258	of	of	IN	B-PP
O	3259	3260	5	5	CD	B-NP
O	3260	3261	-	-	HYPH	I-NP
O	3261	3263	CT	CT	NN	I-NP
O	3264	3271	induces	induce	VBZ	B-VP
O	3272	3273	a	a	DT	B-NP
O	3274	3278	rise	rise	NN	I-NP
O	3279	3281	in	in	IN	B-PP
O	3282	3285	IOP	IOP	NNP	B-NP
O	3285	3286	,	,	,	O
O	3287	3292	which	which	WDT	B-NP
O	3293	3295	is	be	VBZ	B-VP
O	3296	3302	partly	partly	RB	I-VP
O	3303	3305	or	or	CC	I-VP
O	3306	3314	entirely	entirely	RB	I-VP
O	3315	3321	caused	cause	VBN	I-VP
O	3322	3324	by	by	IN	B-PP
O	3325	3327	an	an	DT	B-NP
O	3328	3336	increase	increase	NN	I-NP
O	3337	3339	in	in	IN	B-PP
B-Organism_substance	3340	3347	aqueous	aqueous	JJ	B-NP
I-Organism_substance	3348	3353	humor	humor	NN	I-NP
O	3354	3363	secretion	secretion	NN	I-NP
O	3364	3372	mediated	mediate	VBN	B-VP
O	3373	3375	by	by	IN	B-PP
O	3376	3377	5	5	CD	B-NP
O	3377	3378	-	-	HYPH	I-NP
O	3378	3381	HT7	HT7	NN	I-NP
O	3382	3391	receptors	receptor	NNS	I-NP
O	3392	3393	[	[	(	O
O	3393	3395	84	84	CD	B-NP
O	3395	3396	]	]	)	O
O	3396	3397	.	.	.	O

O	3398	3401	The	The	DT	B-NP
O	3402	3407	other	other	JJ	I-NP
O	3408	3412	type	type	NN	I-NP
O	3413	3415	of	of	IN	B-PP
O	3416	3425	serotonin	serotonin	NN	B-NP
O	3426	3434	receptor	receptor	NN	I-NP
O	3435	3442	present	present	JJ	B-ADJP
O	3443	3445	in	in	IN	B-PP
O	3446	3449	the	the	DT	B-NP
B-Multi-tissue_structure	3450	3453	ICB	ICB	NN	I-NP
O	3454	3456	is	be	VBZ	B-VP
O	3457	3458	a	a	DT	B-NP
O	3459	3460	5	5	CD	I-NP
O	3460	3461	-	-	HYPH	I-NP
O	3461	3464	HT2	HT2	NN	I-NP
O	3465	3469	type	type	NN	I-NP
O	3469	3470	.	.	.	O

O	3471	3480	Serotonin	Serotonin	NN	B-NP
O	3481	3491	stimulates	stimulate	VBZ	B-VP
O	3492	3495	the	the	DT	B-NP
O	3496	3508	accumulation	accumulation	NN	I-NP
O	3509	3511	of	of	IN	B-PP
O	3512	3520	inositol	inositol	NN	B-NP
O	3521	3531	phosphates	phosphate	NNS	I-NP
O	3532	3534	in	in	IN	B-PP
O	3535	3538	the	the	DT	B-NP
B-Multi-tissue_structure	3539	3542	ICB	ICB	NN	I-NP
O	3543	3546	and	and	CC	O
O	3547	3551	this	this	DT	B-NP
O	3552	3558	effect	effect	NN	I-NP
O	3559	3561	is	be	VBZ	B-VP
O	3562	3571	partially	partially	RB	I-VP
O	3572	3584	counteracted	counteract	VBN	I-VP
O	3585	3587	by	by	IN	B-PP
O	3588	3591	the	the	DT	B-NP
O	3592	3593	5	5	CD	I-NP
O	3593	3594	-	-	HYPH	I-NP
O	3594	3597	HT2	HT2	NN	I-NP
O	3598	3609	antagonists	antagonist	NNS	I-NP
O	3610	3620	ketanserin	ketanserin	NN	I-NP
O	3620	3621	,	,	,	O
O	3622	3634	methysergide	methysergide	NN	B-NP
O	3635	3638	and	and	CC	O
O	3639	3648	mianserin	mianserin	NN	B-NP
O	3649	3650	[	[	(	O
O	3650	3652	98	98	CD	B-NP
O	3652	3653	]	]	)	O
O	3653	3654	.	.	.	O

O	3655	3662	Studies	Study	NNS	B-NP
O	3663	3667	with	with	IN	B-PP
O	3668	3678	ketanserin	ketanserin	NN	B-NP
O	3679	3683	have	have	VBP	B-VP
O	3684	3696	demonstrated	demonstrate	VBN	I-VP
O	3697	3701	that	that	IN	B-SBAR
O	3701	3702	,	,	,	O
O	3703	3707	when	when	WRB	B-ADVP
B-Organism_subdivision	3708	3714	orally	orally	RB	B-VP
O	3715	3717	or	or	CC	I-VP
O	3718	3727	topically	topically	RB	I-VP
O	3728	3735	applied	apply	VBN	I-VP
O	3735	3736	,	,	,	O
O	3737	3739	it	it	PRP	B-NP
O	3740	3746	lowers	lower	VBZ	B-VP
O	3747	3750	IOP	IOP	NN	B-NP
O	3751	3753	in	in	IN	B-PP
O	3754	3761	animals	animal	NNS	B-NP
O	3761	3762	,	,	,	O
O	3763	3770	healthy	healthy	JJ	B-NP
O	3771	3781	volunteers	volunteer	NNS	I-NP
O	3782	3785	and	and	CC	B-PP
O	3786	3788	in	in	IN	B-PP
B-Pathological_formation	3789	3801	glaucomatous	glaucomatous	JJ	B-NP
O	3802	3810	patients	patient	NNS	I-NP
O	3811	3812	[	[	(	O
O	3812	3814	26	26	CD	B-NP
O	3814	3815	,	,	,	I-NP
O	3816	3818	34	34	CD	I-NP
O	3818	3819	,	,	,	I-NP
O	3820	3822	37	37	CD	I-NP
O	3822	3823	,	,	,	I-NP
O	3824	3826	64	64	CD	I-NP
O	3826	3827	,	,	,	I-NP
O	3828	3830	75	75	CD	I-NP
O	3830	3831	,	,	,	I-NP
O	3832	3834	88	88	CD	I-NP
O	3834	3835	,	,	,	I-NP
O	3836	3839	113	113	CD	I-NP
O	3839	3840	,	,	,	I-NP
O	3841	3844	126	126	CD	I-NP
O	3844	3845	]	]	)	O
O	3845	3846	.	.	.	O

O	3847	3849	It	It	PRP	B-NP
O	3850	3853	has	have	VBZ	B-VP
O	3854	3858	been	be	VBN	I-VP
O	3859	3869	emphasized	emphasize	VBN	I-VP
O	3870	3874	that	that	IN	B-SBAR
O	3875	3885	ketanserin	ketanserin	NN	B-NP
O	3886	3890	also	also	RB	B-ADVP
O	3891	3900	possesses	possess	VBZ	B-VP
O	3901	3903	an	an	DT	B-NP
O	3904	3912	affinity	affinity	NN	I-NP
O	3913	3916	for	for	IN	B-PP
O	3917	3923	alpha1	alpha1	NN	B-NP
O	3923	3924	-	-	HYPH	B-NP
O	3924	3939	adrenoreceptors	adrenoreceptor	NNS	I-NP
O	3940	3941	[	[	(	O
O	3941	3943	27	27	CD	B-NP
O	3943	3944	,	,	,	I-NP
O	3945	3947	36	36	CD	I-NP
O	3947	3948	,	,	,	I-NP
O	3949	3952	139	139	CD	I-NP
O	3952	3953	]	]	)	O
O	3953	3954	,	,	,	O
O	3955	3958	and	and	CC	O
O	3959	3962	for	for	IN	B-PP
O	3963	3967	this	this	DT	B-NP
O	3968	3974	reason	reason	NN	I-NP
O	3975	3978	the	the	DT	B-NP
O	3979	3986	effects	effect	NNS	I-NP
O	3987	3989	of	of	IN	B-PP
O	3990	4000	ketanserin	ketanserin	NN	B-NP
O	4001	4003	on	on	IN	B-PP
O	4004	4007	IOP	IOP	NNP	B-NP
O	4008	4011	may	may	MD	B-VP
O	4012	4015	not	not	RB	I-VP
O	4016	4018	be	be	VB	I-VP
O	4019	4027	entirely	entirely	RB	I-VP
O	4028	4034	caused	cause	VBN	I-VP
O	4035	4037	by	by	IN	B-PP
O	4038	4041	its	its	PRP$	B-NP
O	4042	4048	action	action	NN	I-NP
O	4049	4051	on	on	IN	B-PP
O	4052	4053	5	5	CD	B-NP
O	4053	4054	-	-	HYPH	I-NP
O	4054	4057	HT2	HT2	NN	I-NP
O	4058	4067	receptors	receptor	NNS	I-NP
O	4067	4068	.	.	.	O

O	4069	4076	However	However	RB	B-ADVP
O	4076	4077	,	,	,	O
O	4078	4082	data	datum	NNS	B-NP
O	4083	4087	from	from	IN	B-PP
O	4088	4093	human	human	JJ	B-NP
O	4094	4101	studies	study	NNS	I-NP
O	4102	4111	conducted	conduct	VBN	B-VP
O	4112	4117	after	after	IN	B-PP
B-Organism_subdivision	4118	4122	oral	oral	JJ	B-NP
O	4123	4125	or	or	CC	I-NP
O	4126	4133	topical	topical	JJ	I-NP
O	4134	4148	administration	administration	NN	I-NP
O	4149	4151	of	of	IN	B-PP
O	4152	4162	ketanserin	ketanserin	NN	B-NP
O	4162	4163	,	,	,	O
O	4164	4166	in	in	IN	B-PP
O	4167	4172	which	which	WDT	B-NP
O	4173	4177	were	be	VBD	B-VP
O	4178	4188	determined	determine	VBN	I-VP
O	4189	4192	the	the	DT	B-NP
O	4193	4203	variations	variation	NNS	I-NP
O	4204	4206	of	of	IN	B-PP
O	4207	4210	IOP	IOP	NN	B-NP
O	4210	4211	,	,	,	O
O	4212	4217	total	total	JJ	B-NP
O	4218	4225	outflow	outflow	NN	I-NP
O	4226	4234	facility	facility	NN	I-NP
O	4235	4238	and	and	CC	O
B-Multi-tissue_structure	4239	4244	pupil	pupil	NN	B-NP
O	4245	4253	diameter	diameter	NN	I-NP
O	4253	4254	,	,	,	O
O	4255	4267	demonstrated	demonstrate	VBD	B-VP
O	4268	4272	that	that	IN	B-SBAR
O	4273	4276	the	the	DT	B-NP
O	4277	4283	alpha1	alpha1	NN	I-NP
O	4283	4284	-	-	HYPH	B-NP
O	4284	4298	adrenoreceptor	adrenoreceptor	NN	I-NP
O	4299	4307	blocking	block	VBG	B-VP
O	4308	4314	effect	effect	NN	B-NP
O	4315	4322	exerted	exert	VBN	B-VP
O	4323	4325	by	by	IN	B-PP
O	4326	4336	ketanserin	ketanserin	NN	B-NP
O	4337	4343	should	should	MD	B-VP
O	4344	4353	represent	represent	VB	I-VP
O	4354	4355	a	a	DT	B-NP
O	4356	4363	further	further	JJ	I-NP
O	4364	4370	aspect	aspect	NN	I-NP
O	4371	4373	of	of	IN	B-PP
O	4374	4377	its	its	PRP$	B-NP
O	4378	4387	mechanism	mechanism	NN	I-NP
O	4388	4390	of	of	IN	B-PP
O	4391	4397	action	action	NN	B-NP
O	4397	4398	,	,	,	O
O	4399	4407	probably	probably	RB	B-ADVP
O	4408	4411	due	due	JJ	B-ADJP
O	4412	4414	to	to	TO	B-PP
O	4415	4416	a	a	DT	B-NP
O	4417	4427	functional	functional	JJ	I-NP
O	4428	4435	sharing	sharing	NN	I-NP
O	4436	4438	of	of	IN	B-PP
O	4439	4444	these	these	DT	B-NP
O	4445	4454	receptors	receptor	NNS	I-NP
O	4455	4456	[	[	(	O
O	4456	4458	64	64	CD	B-NP
O	4458	4459	,	,	,	I-NP
O	4460	4462	87	87	CD	I-NP
O	4462	4463	]	]	)	O
O	4463	4464	.	.	.	O

O	4465	4471	Lastly	Lastly	RB	B-ADVP
O	4471	4472	,	,	,	O
O	4473	4480	already	already	RB	B-ADVP
O	4481	4483	in	in	IN	B-PP
O	4484	4488	1992	1992	CD	B-NP
O	4489	4495	Martin	Martin	NNP	I-NP
O	4496	4499	and	and	CC	O
O	4500	4502	co	co	AFX	B-NP
O	4502	4503	-	-	HYPH	I-NP
O	4503	4510	workers	worker	NNS	I-NP
O	4511	4517	showed	show	VBD	B-VP
O	4518	4521	the	the	DT	B-NP
O	4522	4532	occurrence	occurrence	NN	I-NP
O	4533	4535	of	of	IN	B-PP
O	4536	4537	a	a	DT	B-NP
O	4538	4549	significant	significant	JJ	I-NP
O	4550	4561	correlation	correlation	NN	I-NP
O	4562	4569	between	between	IN	B-PP
O	4570	4573	the	the	DT	B-NP
O	4574	4581	content	content	NN	I-NP
O	4582	4584	of	of	IN	B-PP
O	4585	4594	serotonin	serotonin	NN	B-NP
O	4595	4597	in	in	IN	B-PP
O	4598	4601	the	the	DT	B-NP
B-Organism_substance	4602	4609	aqueous	aqueous	JJ	I-NP
I-Organism_substance	4610	4615	humor	humor	NN	I-NP
O	4616	4619	and	and	CC	I-NP
O	4620	4623	IOP	IOP	NN	I-NP
O	4624	4626	in	in	IN	B-PP
O	4627	4630	the	the	DT	B-NP
O	4631	4636	human	human	JJ	I-NP
B-Organ	4637	4640	eye	eye	NN	I-NP
O	4641	4642	[	[	(	O
O	4642	4644	85	85	CD	B-NP
O	4644	4645	]	]	)	O
O	4645	4646	.	.	.	O

O	4647	4649	In	In	IN	B-PP
O	4650	4654	1981	1981	CD	B-NP
O	4654	4655	,	,	,	O
O	4656	4660	Moro	Moro	NNP	B-NP
O	4661	4664	and	and	CC	O
O	4665	4668	his	his	PRP$	B-NP
O	4669	4682	collaborators	collaborator	NNS	I-NP
O	4683	4688	found	find	VBD	B-VP
O	4689	4693	that	that	IN	B-SBAR
O	4694	4706	intravitreal	intravitreal	JJ	B-NP
O	4707	4716	injection	injection	NN	I-NP
O	4717	4719	of	of	IN	B-PP
O	4720	4721	5	5	CD	B-NP
O	4721	4722	,	,	,	I-NP
O	4723	4724	6	6	CD	I-NP
O	4724	4725	-	-	HYPH	I-NP
O	4725	4744	dihydroxytryptamine	dihydroxytryptamine	NN	I-NP
O	4744	4745	,	,	,	O
O	4746	4747	a	a	DT	B-NP
O	4748	4760	serotonergic	serotonergic	JJ	I-NP
O	4761	4771	neurotoxin	neurotoxin	NN	I-NP
O	4771	4772	,	,	,	O
O	4773	4779	causes	cause	VBZ	B-VP
O	4780	4786	miosis	miosis	NN	B-NP
O	4787	4788	[	[	(	O
O	4788	4790	91	91	CD	B-NP
O	4790	4791	]	]	)	O
O	4791	4792	.	.	.	O

O	4793	4796	The	The	DT	B-NP
O	4797	4811	identification	identification	NN	I-NP
O	4812	4814	of	of	IN	B-PP
O	4815	4816	5	5	CD	B-NP
O	4816	4817	-	-	HYPH	I-NP
O	4817	4820	HT7	HT7	NN	I-NP
O	4820	4821	,	,	,	B-PP
O	4822	4825	but	but	CC	I-PP
O	4826	4829	not	not	RB	B-PP
O	4830	4832	of	of	IN	I-PP
O	4833	4834	5	5	CD	B-NP
O	4834	4835	-	-	HYPH	I-NP
O	4835	4838	HT1	HT1	NN	I-NP
O	4839	4848	receptors	receptor	NNS	I-NP
O	4849	4851	in	in	IN	B-PP
O	4852	4855	the	the	DT	B-NP
O	4856	4862	rabbit	rabbit	NN	I-NP
B-Multi-tissue_structure	4863	4867	iris	iris	NN	I-NP
O	4867	4868	,	,	,	O
O	4869	4877	suggests	suggest	VBZ	B-VP
O	4878	4882	that	that	IN	B-SBAR
O	4883	4887	this	this	DT	B-NP
O	4888	4898	population	population	NN	I-NP
O	4899	4901	of	of	IN	B-PP
O	4902	4914	serotonergic	serotonergic	JJ	B-NP
O	4915	4924	receptors	receptor	NNS	I-NP
O	4925	4927	is	be	VBZ	B-VP
O	4928	4936	involved	involve	VBN	I-VP
O	4937	4939	in	in	IN	B-PP
O	4940	4943	the	the	DT	B-NP
O	4944	4954	relaxation	relaxation	NN	I-NP
O	4955	4957	of	of	IN	B-PP
O	4958	4961	the	the	DT	B-NP
B-Tissue	4962	4971	sphincter	sphincter	NN	I-NP
O	4972	4974	of	of	IN	B-PP
O	4975	4978	the	the	DT	B-NP
B-Multi-tissue_structure	4979	4984	pupil	pupil	NN	I-NP
O	4984	4985	.	.	.	O

O	4986	4988	In	In	IN	B-PP
O	4989	4993	fact	fact	NN	B-NP
O	4993	4994	,	,	,	O
O	4995	4998	one	one	CD	B-NP
O	4999	5001	of	of	IN	B-PP
O	5002	5005	the	the	DT	B-NP
O	5006	5014	function	function	NN	I-NP
O	5015	5024	correlate	correlate	VB	B-VP
O	5025	5027	to	to	TO	B-PP
O	5028	5029	5	5	CD	B-NP
O	5029	5030	-	-	HYPH	I-NP
O	5030	5033	HT7	HT7	NN	I-NP
O	5034	5042	receptor	receptor	NN	I-NP
O	5043	5053	activation	activation	NN	I-NP
O	5054	5062	includes	include	VBZ	B-VP
B-Tissue	5063	5069	smooth	smooth	JJ	B-NP
I-Tissue	5070	5076	muscle	muscle	NN	I-NP
O	5077	5087	relaxation	relaxation	NN	I-NP
O	5088	5096	observed	observe	VBN	B-VP
O	5097	5099	in	in	IN	B-PP
O	5100	5101	a	a	DT	B-NP
O	5102	5109	variety	variety	NN	I-NP
O	5110	5112	of	of	IN	B-PP
O	5113	5121	isolated	isolate	VBN	B-NP
B-Tissue	5122	5128	tissue	tissue	NN	I-NP
O	5129	5141	preparations	preparation	NNS	I-NP
O	5141	5142	,	,	,	O
O	5143	5145	in	in	IN	B-PP
O	5146	5151	which	which	WDT	B-NP
O	5152	5161	elevation	elevation	NN	B-NP
O	5162	5164	of	of	IN	B-PP
O	5165	5169	cAMP	cAMP	NN	B-NP
O	5170	5183	concentration	concentration	NN	I-NP
O	5184	5187	was	be	VBD	B-VP
O	5188	5192	also	also	RB	I-VP
O	5193	5201	detected	detect	VBN	I-VP
O	5202	5203	[	[	(	B-NP
O	5203	5204	3	3	CD	I-NP
O	5204	5205	,	,	,	I-NP
O	5206	5208	44	44	CD	I-NP
O	5208	5209	]	]	)	O
O	5209	5210	.	.	.	O

O	5211	5218	Further	Further	JJ	B-NP
O	5219	5227	evidence	evidence	NN	I-NP
O	5228	5231	for	for	IN	B-PP
O	5232	5235	the	the	DT	B-NP
O	5236	5245	mediation	mediation	NN	I-NP
O	5246	5248	of	of	IN	B-PP
O	5249	5252	the	the	DT	B-NP
O	5253	5261	relaxant	relaxant	JJ	I-NP
O	5262	5270	response	response	NN	I-NP
O	5271	5274	via	via	IN	B-PP
O	5275	5278	the	the	DT	B-NP
O	5279	5280	5	5	CD	I-NP
O	5280	5281	-	-	HYPH	I-NP
O	5281	5284	HT7	HT7	NN	I-NP
O	5285	5293	receptor	receptor	NN	I-NP
O	5294	5296	is	be	VBZ	B-VP
O	5297	5305	provided	provide	VBN	I-VP
O	5306	5308	by	by	IN	B-PP
O	5309	5312	the	the	DT	B-NP
O	5313	5325	localization	localization	NN	I-NP
O	5326	5328	of	of	IN	B-PP
O	5329	5338	messenger	messenger	NN	B-NP
O	5339	5350	ribonucleic	ribonucleic	JJ	I-NP
O	5351	5355	acid	acid	NN	I-NP
O	5356	5367	transcripts	transcript	NNS	I-NP
O	5368	5376	encoding	encode	VBG	B-VP
O	5377	5380	the	the	DT	B-NP
O	5381	5382	5	5	CD	I-NP
O	5382	5383	-	-	HYPH	I-NP
O	5383	5386	HT7	HT7	NN	I-NP
O	5387	5395	receptor	receptor	NN	I-NP
O	5396	5398	in	in	IN	B-PP
O	5399	5403	many	many	JJ	B-NP
B-Multi-tissue_structure	5404	5409	blood	blood	NN	I-NP
I-Multi-tissue_structure	5410	5417	vessels	vessel	NNS	I-NP
O	5418	5419	[	[	(	O
O	5419	5421	67	67	CD	B-NP
O	5421	5422	]	]	)	O
O	5422	5423	.	.	.	O

O	5424	5428	This	This	DT	B-NP
O	5429	5441	hypothesized	hypothesize	VBN	I-NP
O	5442	5451	mechanism	mechanism	NN	I-NP
O	5452	5454	of	of	IN	B-PP
O	5455	5461	action	action	NN	B-NP
O	5462	5464	is	be	VBZ	B-VP
O	5465	5469	also	also	RB	I-VP
O	5470	5479	supported	support	VBN	I-VP
O	5480	5482	by	by	IN	B-PP
O	5483	5486	the	the	DT	B-NP
O	5487	5491	fact	fact	NN	I-NP
O	5492	5496	that	that	IN	B-SBAR
O	5497	5504	various	various	JJ	B-NP
O	5505	5510	other	other	JJ	I-NP
O	5511	5519	receptor	receptor	NN	I-NP
O	5520	5525	types	type	NNS	I-NP
O	5525	5526	,	,	,	O
O	5527	5531	also	also	RB	B-ADVP
O	5532	5542	positively	positively	RB	B-VP
O	5543	5550	coupled	couple	VBN	I-VP
O	5551	5553	to	to	TO	B-PP
O	5554	5558	cAMP	cAMP	NN	B-NP
O	5558	5559	,	,	,	O
O	5560	5562	in	in	IN	B-PP
O	5563	5566	the	the	DT	B-NP
B-Multi-tissue_structure	5567	5571	iris	iris	NN	I-NP
O	5572	5577	cause	cause	VB	B-VP
O	5578	5588	relaxation	relaxation	NN	B-NP
O	5589	5591	of	of	IN	B-PP
O	5592	5595	the	the	DT	B-NP
B-Tissue	5596	5605	sphincter	sphincter	NN	I-NP
I-Tissue	5606	5612	muscle	muscle	NN	I-NP
O	5613	5614	[	[	(	B-NP
O	5614	5615	1	1	CD	I-NP
O	5615	5616	,	,	,	I-NP
O	5617	5619	28	28	CD	I-NP
O	5619	5620	]	]	)	O
O	5620	5621	.	.	.	O

